Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-07-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于子公司向银行申请综合授信及流动资金贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about its subsidiary applying for comprehensive credit and working capital loans from banks. It details the loan amounts, terms, and the subsidiary's financial and operational background. The document includes board and supervisory opinions approving the financing. There are no financial statements or detailed financial performance data presented, nor is this a report or transcript. The content focuses on financing activities and capital structure changes related to loans. Therefore, this fits the category of Capital/Financing Update (CAP). The document length is about 2074 characters, which is consistent with an announcement rather than a full report.
2020-07-27 Chinese
关于增补第四届董事会董事的公告
Board/Management Information Classification · 95% confidence The document is an announcement from a company about the nomination and addition of new members to its board of directors. It details the resignation of an independent director, the nomination of new non-independent and independent directors, their qualifications, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board composition and related governance matters. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 2766 characters, which is consistent with an announcement rather than a full report.
2020-07-27 Chinese
独立董事候选人声明
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of Yunnan Watson Biotechnology Co., Ltd. It details the candidate's qualifications, compliance with relevant laws and regulations, and independence criteria. The content is a personal statement related to board membership qualifications rather than a report on financial performance, management changes, or shareholder voting results. It does not contain financial data, earnings information, or meeting materials. The document is a declaration related to board/management information, specifically concerning the appointment or candidacy of an independent director. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length (6927 characters) supports it being a full declaration rather than a brief announcement or certification.
2020-07-27 Chinese
关于召开2020年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2020 third extraordinary general meeting of shareholders for Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, voting procedures (including cumulative voting), proposals to be voted on (such as election of non-independent and independent directors and supervisors), registration methods, and proxy authorization forms. The content focuses on the organization and conduct of a shareholders' meeting rather than the results of voting or the meeting itself. It is not a report of voting results, nor is it a management or financial report. The document is a formal announcement and notice to shareholders about the meeting and how to participate. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-07-27 Chinese
独立董事关于第四届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters related to the company's fourth board meeting, including nominations of board members and approval of financing activities by a subsidiary. It discusses compliance with laws and regulations, qualifications of director candidates, and approval of loan applications. The content focuses on board/management information and governance-related opinions rather than financial results or report announcements. The document length is short (1957 characters) and does not contain financial statements or detailed financial data. It is not an announcement of a report publication but a formal opinion related to board matters and financing approvals. Therefore, the most appropriate classification is Board/Management Information (MANG).
2020-07-27 Chinese
第四届监事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Yunnan Watson Biotechnology Co., Ltd. It details the decisions made in the eighth meeting of the fourth Supervisory Board, including nominations and approvals related to credit facilities and guarantees for subsidiaries. The document includes voting results and references to further announcements on a regulatory disclosure website. It does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. It is not an annual or interim report, nor an earnings release. It is a formal announcement of board-level decisions and approvals, which fits best under Board/Management Information (MANG). The document length is short (1564 characters), and it is not merely announcing the publication of a report but is itself the resolution announcement. Therefore, the classification is MANG with high confidence.
2020-07-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.